Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Apr 7, 2009; 15(13): 1594-1599
Published online Apr 7, 2009. doi: 10.3748/wjg.15.1594
Published online Apr 7, 2009. doi: 10.3748/wjg.15.1594
Table 3 Response and remission rates at 8 wk and CRP levels with MMF therapy
| CD patients n = 9 | UC/IBDU patients n = 5 | |
| emission | 66.7% (6/9) | 80% (4/5) |
| Response | 66.7% (6/9) | 80% (4/5) |
| Intolerant | 22.2% (2/9) | 20% (1/5) |
| Ineffective | 11.1% (1/9) | 0% (0/5) |
| Raised CRP | ||
| In responders | 0% (0/6) | 0% (4/5) |
| In non ponders | 33.3% (1/3) | 100% (1/1) |
- Citation: Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 2009; 15(13): 1594-1599
- URL: https://www.wjgnet.com/1007-9327/full/v15/i13/1594.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.1594